The declaration, made Thursday, sent Novo Nordisk shares down as much as 7.4% in Copenhagen trading. Wegovy, which contains the active ingredient semaglutide, has become a sensation for it’s effectiveness in promoting weight loss, but its high price-over $1,300 per month-has limited access for many.
what exactly dose it mean to “compound” a drug like Wegovy? Compounding pharmacies combine ingredients to create a customized medication tailored to a patient’s specific needs, often offering a more affordable option than brand-name drugs. Hims & Hers plans to offer the compounded version at a price of $249 per month, significantly undercutting Wegovy’s list price.
The move by Hims & Hers isn’t without potential complications. The Food and Drug Administration (FDA) doesn’t review compounded drugs in the same way it does approved medications, raising concerns about quality control and consistency. However, Hims & Hers stated that it is working with a network of licensed pharmacies to ensure the compounded Wegovy meets stringent quality standards.
The Broader Implications for Weight-Loss Medications
The entrance of a lower-cost alternative could reshape the landscape of the weight-loss drug market, perhaps increasing access for a wider range of patients.
Analysts are divided on the long-term impact. some believe that the compounded version will only capture a small portion of the market, as patients may prefer the brand-name drug due to concerns about quality or efficacy. others suggest that it could put meaningful pressure on Novo Nordisk to lower its price or face a considerable loss of market share.
Navigating the Future of Wegovy Access
The situation highlights the
Related reading
